Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Bioanalysis ; 14(5): 267-278, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35195037

ABSTRACT

Background: The degree of human hepatocyte replacement in chimeric mice with humanized liver has previously been shown to correlate with human plasma albumin measurements. However, there are no reports that directly compare the remaining endogenous mouse albumin with the newly expressed human albumin following engraftment. To better understand the disposition of serum albumin in PXB-mice, we developed a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to simultaneously quantitate both human and mouse albumin from plasma. Results: A robust correlation was observed between the serum human albumin levels measured by LC-MS/MS and the estimated replacement index of PXB-mice. Conclusion: All data were shown to be specific and suitable to accurately quantify both human and mouse albumin from plasma of chimeric mice with humanized livers.


Subject(s)
Serum Albumin, Human , Tandem Mass Spectrometry , Chimera , Chromatography, Liquid , Hepatocytes , Humans , Liver , Tandem Mass Spectrometry/methods
2.
Bioanalysis ; 13(3): 147-159, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33543654

ABSTRACT

Background: Surrogate monoclonal antibodies (mAbs) used in preclinical in vivo studies can be challenging to quantify due to lack of suitable immunoaffinity reagents or unavailability of the mAb protein sequence. Generic immunoaffinity reagents were evaluated to develop sensitive LC-MS/MS assays. Peptides of unknown sequence can be used for selective LC-MS quantification. Results: anti-mouse IgG1 was found to be an effective immunoaffinity reagent, enabling quantification of mouse IgG1 mAbs in mouse serum. Selective peptides of unknown sequence were applied for multiplex LC-MS quantification of two rat mAbs co-dosed in mouse. Conclusion: Generic anti-mouse IgG subtype-specific antibodies can be used to improve assay sensitivity and peptides of unknown sequence can be used to quantify surrogate mAbs when the mAb protein sequence in unavailable.


Subject(s)
Antibodies, Monoclonal/blood , Chromatography, Liquid/methods , Tandem Mass Spectrometry/methods , Animals , Humans , Mice , Rats
3.
Bioanalysis ; 4(18): 2213-26, 2012 Sep.
Article in English | MEDLINE | ID: mdl-23046264

ABSTRACT

Over 400 professionals representing pharmaceutical companies, CROs, and multiple regulatory agencies participated in the 6th Workshop on Recent Issues in Bioanalysis (WRIB). Like the previous sessions, this event was in the format of a practical, focused, highly interactive and informative workshop aiming for high-quality, improved regulatory compliance and scientific excellence. Numerous 'hot' topics in bioanalysis of both small and large molecules were shared and discussed, leading to consensus and recommendations among panelists and attendees representing the bioanalytical community. The major outcome of this year's workshop was the noticeable alignment of multiple bioanalytical guidance/guidelines from different regulatory agencies. This represents a concrete step forward in the global harmonization of bioanalytical activities. The present 2012 White Paper acts as a practical and useful reference document that provides key information and solutions on several topics and issues in the constantly evolving world of bioanalysis.


Subject(s)
Chromatography, High Pressure Liquid/methods , Guidelines as Topic , Immunoassay/methods , Mass Spectrometry/methods , Pharmaceutical Preparations/analysis , Recombinant Proteins/analysis , Calibration , Chromatography, High Pressure Liquid/standards , Dried Blood Spot Testing/methods , Drug Industry , Government Regulation , Humans , Immunoassay/standards , Mass Spectrometry/standards , Reproducibility of Results , Sensitivity and Specificity , Validation Studies as Topic
4.
Sci Transl Med ; 4(126): 126ra35, 2012 Mar 21.
Article in English | MEDLINE | ID: mdl-22440737

ABSTRACT

Despite the need for new antibiotics to treat drug-resistant bacteria, current clinical combinations are largely restricted to ß-lactam antibiotics paired with ß-lactamase inhibitors. We have adapted a Staphylococcus aureus antisense knockdown strategy to genetically identify the cell division Z ring components-FtsA, FtsZ, and FtsW-as ß-lactam susceptibility determinants of methicillin-resistant S. aureus (MRSA). We demonstrate that the FtsZ-specific inhibitor PC190723 acts synergistically with ß-lactam antibiotics in vitro and in vivo and that this combination is efficacious in a murine model of MRSA infection. Fluorescence microscopy localization studies reveal that synergy between these agents is likely to be elicited by the concomitant delocalization of their cognate drug targets (FtsZ and PBP2) in MRSA treated with PC190723. A 2.0 Å crystal structure of S. aureus FtsZ in complex with PC190723 identifies the compound binding site, which corresponds to the predominant location of mutations conferring resistance to PC190723 (PC190723(R)). Although structural studies suggested that these drug resistance mutations may be difficult to combat through chemical modification of PC190723, combining PC190723 with the ß-lactam antibiotic imipenem markedly reduced the spontaneous frequency of PC190723(R) mutants. Multiple MRSA PC190723(R) FtsZ mutants also displayed attenuated virulence and restored susceptibility to ß-lactam antibiotics in vitro and in a mouse model of imipenem efficacy. Collectively, these data support a target-based approach to rationally develop synergistic combination agents that mitigate drug resistance and effectively treat MRSA infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , beta-Lactams/pharmacology , Animals , Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Cell Division/drug effects , Crystallography, X-Ray , Cytoskeletal Proteins/antagonists & inhibitors , Cytoskeletal Proteins/chemistry , Cytoskeletal Proteins/metabolism , Disease Models, Animal , Drug Resistance, Bacterial/drug effects , Drug Synergism , Gene Regulatory Networks/genetics , Guanosine Diphosphate , Imipenem/pharmacology , Methicillin-Resistant Staphylococcus aureus/cytology , Methicillin-Resistant Staphylococcus aureus/pathogenicity , Mice , Microbial Sensitivity Tests , Mutation/genetics , Protein Structure, Secondary , Protein Transport/drug effects , Pyridines/chemistry , Pyridines/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Thiazoles/chemistry , Thiazoles/pharmacology , Virulence/drug effects , beta-Lactams/therapeutic use
5.
J Lipid Res ; 52(8): 1494-9, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21642745

ABSTRACT

A positive correlation between stearoyl-CoA desaturase (SCD)1 expression and metabolic diseases has been reported in rodents and humans. These findings indicate that SCD1 is a promising therapeutic target for the chronic treatment of diabetes and dyslipidemia. The SCD1 enzyme is expressed at high levels in several human tissues and is required for the biosynthesis of monounsaturated fatty acids, which are involved in many biological processes. Liver-targeted SCD inhibitors were designed to pharmacologically manipulate SCD1 activity in the liver to avoid adverse events due to systemic inhibition. This article describes the development of a plasma-based SCD assay to assess the level of SCD inhibition, which is defined in this article as target engagement. Essentially, animals are dosed with an exogenous deuterated tracer (d7-stearic acid) as substrate, and the converted d7-oleic acid product is measured to monitor SCD1 inhibition. This study reveals that this plasma-based assay correlates with liver SCD1 inhibition and can thus have clinical utility.


Subject(s)
Acetates , Biological Assay/methods , Diabetes Mellitus/blood , Dyslipidemias/blood , Liver/metabolism , Oleic Acid/analysis , Stearoyl-CoA Desaturase/antagonists & inhibitors , Tetrazoles , Acetates/administration & dosage , Acetates/pharmacokinetics , Animals , Carbon Radioisotopes/analysis , Chromatography, High Pressure Liquid , Deuterium/analysis , Diabetes Mellitus/drug therapy , Diabetes Mellitus/physiopathology , Dyslipidemias/drug therapy , Dyslipidemias/physiopathology , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacokinetics , Humans , Male , Mass Spectrometry , Molecular Targeted Therapy/methods , Oleic Acid/metabolism , Plasma/chemistry , Plasma/metabolism , Rats , Rats, Sprague-Dawley , Stearoyl-CoA Desaturase/metabolism , Tetrazoles/administration & dosage , Tetrazoles/pharmacokinetics
6.
J Med Chem ; 54(14): 5082-96, 2011 Jul 28.
Article in English | MEDLINE | ID: mdl-21661758

ABSTRACT

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.


Subject(s)
Acetates/chemical synthesis , Hypoglycemic Agents/chemical synthesis , Hypolipidemic Agents/chemical synthesis , Liver/enzymology , Stearoyl-CoA Desaturase/antagonists & inhibitors , Tetrazoles/chemical synthesis , Acetates/chemistry , Acetates/pharmacology , Animals , Cell Line , Diffusion , Dogs , Female , Harderian Gland/metabolism , Hep G2 Cells , Hepatocytes/metabolism , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Hypolipidemic Agents/chemistry , Hypolipidemic Agents/pharmacology , In Vitro Techniques , Liver-Specific Organic Anion Transporter 1 , Macaca mulatta , Male , Mice , Mice, Inbred C57BL , Microsomes/metabolism , Organic Anion Transporters/metabolism , Organic Anion Transporters, Sodium-Independent/metabolism , Rats , Rats, Sprague-Dawley , Skin/metabolism , Solute Carrier Organic Anion Transporter Family Member 1B3 , Species Specificity , Structure-Activity Relationship , Tetrazoles/chemistry , Tetrazoles/pharmacology , Tissue Distribution
7.
Anim Cogn ; 9(1): 1-12, 2006 Jan.
Article in English | MEDLINE | ID: mdl-15750805

ABSTRACT

In several species, the ability to locate a disappearing object is an adaptive component of predatory and social behaviour. In domestic dogs, spatial memory for hidden objects is primarily based on an egocentric frame of reference. We investigated the geometric components of egocentric spatial information used by domestic dogs to locate an object they saw move and disappear. In experiment 1, the distance and the direction between the position of the animal and the hiding location were put in conflict. Results showed that the dogs primarily used the directional information between their own spatial coordinates and the target position. In experiment 2, the accuracy of the dogs in finding a hidden object by using directional information was estimated by manipulating the angular deviation between adjacent hiding locations and the position of the animal. Four angular deviations were tested: 5, 7.5, 10 and 15 degrees . Results showed that the performance of the dogs decreased as a function of the angular deviations but it clearly remained well above chance, revealing that the representation of the dogs for direction is precise. In the discussion, we examine how and why domestic dogs determine the direction in which they saw an object disappear.


Subject(s)
Dogs/psychology , Motion Perception , Space Perception , Animals , Female , Form Perception , Male , Mental Recall , Orientation , Problem Solving
8.
Anim Cogn ; 6(1): 1-10, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12658530

ABSTRACT

Two experiments explored the duration of dogs' working memory in an object permanence task: a delay was introduced between the disappearance of a moving object behind a box and the beginning of the search by the animal. In experiment 1, the dogs were tested with retention intervals of 0, 10, 30, and 60 s. Results revealed that the dogs' accuracy declined as a function of the length of the retention interval but remained above chance for each retention interval. In experiment 2, with new subjects, longer retention intervals (0, 30, 60, 120, and 240 s) were presented to the dogs. Results replicated findings from experiment 1 and revealed that the dogs' accuracy remained higher than chance level with delays up to 240 s. In both experiments, the analysis of errors also showed that the dogs searched as a function of the proximity of the target box and were not subject to intertrial proactive interference. In the discussion, we explore different alternatives to explain why dogs' search behaviour for hidden objects decreased as a function of the retention intervals.


Subject(s)
Dogs/psychology , Exploratory Behavior , Memory , Animals , Female , Male , Visual Perception
10.
Prostate ; 51(2): 117-25, 2002 May 01.
Article in English | MEDLINE | ID: mdl-11948966

ABSTRACT

BACKGROUND: Mechanisms triggering prostatic NE differentiation are poorly understood. Since dog and man naturally develop prostatic proliferative diseases with age, our objectives were to confirm the presence of NE cells in the dog prostate and test their hormonal regulation in both species. METHODS: Serotonin staining was examined by immunohistochemistry in 37 dog prostates: 17 from intact and 20 from castrated animals. In intact dogs, 9 prostates were normal and 8 hyperplastic. In the castrated group, 6 dogs were left untreated while androgens and estrogens were administered to 7 dogs, each. Human prostates were from 48 prostate cancer patients; half of them were submitted to androgen ablation prior to prostatectomy. The density of serotonin-positive NE cells was expressed relatively to the number of acini. RESULTS: Serotonin-positive NE cells were morphologically similar in dog and human prostates and identified in all groups, independent of the hormonal status. NE cell densities were within the same range in normal and hyperplastic dog prostates but significantly higher after castration. Androgens and estrogens after castration restored NE cell density to normal values and induced luminal differentiation and basal metaplasia, respectively. In human, the density of serotonin-positive NE cells was also significantly higher in benign glands after androgen ablation. CONCLUSIONS: The dog is a suitable animal model and mimics the human, since androgen ablation favored prostatic NE differentiation in both species. The down-regulation elicited by steroids suggests that the process may be reversible and hormonally-repressed.


Subject(s)
Androgen Antagonists/pharmacology , Cell Differentiation , Prostate/cytology , Prostatic Neoplasms/physiopathology , Serotonin/analysis , Animals , Disease Models, Animal , Dogs , Down-Regulation , Humans , Immunohistochemistry , Male , Neurosecretory Systems/cytology , Prognosis , Prostatectomy
SELECTION OF CITATIONS
SEARCH DETAIL
...